Rosetta Genomics and Rabin Medical Center Announce Collaboration Focused on MicroRNA-Based Diagnostics
News Jun 27, 2008
The collaboration will leverage microRNAs' significant potential as highly sensitive and specific biomarkers, to develop a wide range of diagnostic and prognostic tests. This is the company's first collaboration to include a focus on diagnostics for women's health indications.
"MicroRNAs' unique characteristics as sensitive and specific biomarkers, coupled with our strong development engines, enable us to expand and advance our development programs outside the oncology field," said Amir Avniel, President and CEO of Rosetta Genomics. "There is true unmet medical need for better diagnostics in Women's Health, and I am confident that The Rabin Medical Center's world-renowned researchers will assist us in bringing better diagnostics to patients worldwide."
"As a leading research and clinical center at the forefront of science, we understand the importance of transforming cutting-edge technologies into next-generation products that will benefit patients worldwide," said Dr. Eyran Halpern, CEO of the Rabin Medical Center. "MicroRNAs are proving to be highly effective biomarkers for a wide range of indications. I believe that by leveraging the proprietary technologies developed by Rosetta Genomics, this collaboration will be a fruitful one."
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE